The dual variable domain immunoglobulin (DVD-Ig™) protein is a new type of dual-specific IgG. As a novel therapeutic class, the great potential of the DVD-Ig protein is to simultaneously target two mediators of disease by a single pharmaceutical entity. The molecule contains an Fc region and constant regions in a configuration similar to a conventional IgG; however, the DVD-Ig protein is unique in that each arm of the molecule contains two variable domains (VDs). The VDs within an arm are linked in tandem and can possess different binding specificities. Here, we discuss critical design features of the DVD-Ig protein and describe a methodology for cloning, expressing, and purifying the molecules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-61779-921-1_9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses.
Med Microbiol Immunol
November 2024
Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
The concern of COVID-19 persists due to the continuous emergence of variants and the potential spillover of animal coronaviruses. The broad-spectrum neutralizing antibodies play a pivotal role in the prevention and treatment of coronavirus (CoV) infections. Here, we constructed 18 bi-specific antibodies (bsAbs) using 9 antibodies isolated from COVID-19 convalescents and vaccinated individuals, designed as dual variable domain immunoglobulin (DVD-Ig).
View Article and Find Full Text PDFStructural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies.
Front Immunol
June 2024
Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Article Synopsis
- Bispecific T-cell-engaging antibodies are complex drugs that enhance T cells' ability to target and destroy tumor cells, with seven already approved for use.* -
- They come in two main formats, IgG-like and non-IgG-like, which may affect their potency and how they work, indicating a need for further research.* -
- This study compared two types of bispecific antibodies targeting EGFR and CD3 in breast and ovarian cancer cells, finding that structural differences significantly influence their effectiveness and mechanisms in fighting cancer.*
A High-Throughput MEMS-Based Differential Scanning Calorimeter for Direct Thermal Characterization of Antibodies.
Biosensors (Basel)
June 2022
Department of Mechanical Engineering, Virginia Polytechnic Institute and State University, Blacksburg, VA 24060, USA.
Calorimeters, which can be used for rapid thermal characterization of biomolecules, are getting intense attention in drug development. This paper presents a novel MEMS-based differential scanning calorimeter (DSC) for direct thermal characterization of protein samples. The DSC consisted of a pair of temperature sensors made by vanadium oxide (VO) film with a temperature coefficient of resistivity of -0.
View Article and Find Full Text PDFBispecific Antibody Designed for Targeted NK Cell Activation and Functional Assessment for Biomedical Applications.
ACS Appl Mater Interfaces
September 2021
Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
Article Synopsis
- Natural killer (NK) cells are important for immune response, and their activity can indicate the severity of various diseases, but current testing methods face challenges in preparation and consistency.
- New bispecific antibodies (BsAbs) targeting specific NK cell receptors have been developed to help assess NK cell functions more easily and reliably by enhancing their activation and response.
- These NK cell activator antibodies (NKABs) show effectiveness in detecting NK cell dysfunctions in certain diseases, demonstrating their potential for use in clinical diagnostics and prognosis.
A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects and .
Front Immunol
June 2021
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Overexpression of HER2 has been reported in many types of cancer, making it a perfect candidate for targeted immunotherapy. The combination of two FDA approved monoclonal antibodies (mAbs), trastuzumab and pertuzumab, has more robust anti-tumor activity in patients with HER2-overexpressing breast cancer. We recently produced a new humanized anti-HER2 mAb, hersintuzumab, which recognizes a different epitope than trastuzumab and pertuzumab on HER2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!